



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Feasibility of stratification of sales data

ESVAC Stakeholders annual meeting 2016

Presented by Jordi Torren on 2 March 2016
Scientific Administrator, Veterinary Medicines Division

An agency of the European Union





Content of the presentation

- Feasibility and main concept of stratification of sales data.
- Benefits
- Providers of ESVAC data by source
- Sales from MAH
- Relationship between sales of antimicrobials and resistance in the EU
- Conclusions



Stratification of sales data

- ESVAC project will, together with the MSs, explore if it is feasible to estimate the consumption per species based on an approximate allocation of the proportion of total sales that are used in each species for which an antimicrobial is indicated.
- Would be based on direct attribution of sales to one animal species for those products for which only one animal species is authorised (circa 30% of products), and by attributing proportions of sales to each major animal species (pigs, poultry, cattle, companion animals and others).



Stratification of sales data (cont.)

- Estimates could be from the Marketing Authorisation Holders.
- Could enhance the analysis and reporting of the stratified sales data by use of the established DDDvet and DCDvet.
- Could provide an estimate of the use per species until such time as systems to measure actual use come on line.
- Parallel activity and not an alternative or competing system.




Stratification of sales data

- The approach might be relevant for countries aiming to set up systems to collect data from e.g. only one animal species, or to supplement the collection of data from e.g. a representative number of farms.
- It is envisaged that the review of the veterinary medicines legislation will require Member States to collect antimicrobial consumption data by species.
 - The stratification should be viewed as an interim approach until systems to collect data by species are in place.



Providers of ESVAC data by source





Sales from MAH, combination of MAH+wholesalers, continuous data

	Austria	Denmark	France	Germany	Ireland	Italy	Netherlands	Spain	United Kingdom	Subtotal	Total 26 countries	% coverage
Tonnes sold 2013	55	108	681	1527	100	1318	226	2202	422	6639	8060	82%

Protocol to be defined with ESVAC sales Expert Advisory Group.
Collaboration with MAHs will be paramount for the success of the current proposal.



Relationship between sales of antimicrobials and resistance in the EU

The JIACRA report analyses data on resistance and sales of antimicrobials from humans and animals.

A “summary indicator” of resistance at the MS level, Ind_{Res} , was calculated.

$$Ind_{Res} = \frac{1}{PCU_{cattle} + PCU_{fowl} + PCU_{pigs}} \cdot (PCU_{cattle} \cdot Res_{cattle} + PCU_{fowl} \cdot Res_{fowl} + PCU_{pigs} \cdot Res_{pigs})$$

A simplified approach could be considered where the sales of products authorised per one animal species could be combined with an attribution according to the species authorised and the PCU.



Conclusions

- ESVAC will study the feasibility of the stratification
- Stratification might complement other systems
- Most of ESVAC sales from MAH
- Protocol to be defined with ESVAC sales Expert Advisory Group.
- Collaboration with MAHs will be paramount for the success of the current proposal.
- A simplified stratification could be used for JIACRA report



Thank you for your attention

Further information

ESVAC@ema.europa.eu

European Medicines Agency

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom

Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555

Send a question via our website www.ema.europa.eu/contact

Follow us on  **@EMA_News**